The LEVANT i (lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: First-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty

JACC: Cardiovascular Interventions

Volumn 7, Issue 1, 2014, Pages 10-19

  Scheinert, Dierk ^a   Duda, Stephan ^b   Zeller, Thomas ^c   Krankenberg, Hans ^d   Ricke, Jens ^e   Bosiers, Marc ^f   Tepe, Gunnar ^g   Naisbitt, Scott ^h   Rosenfield, Kenneth ⁱ  

^a Park Hospital Leipzig   (Germany)

^b Jewish Hospital   (Germany)

^c UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^d UNIVERSITY HEART CENTER HAMBURG   (Germany)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

^f St Blasius Hospital   (Belgium)

^g RoMed Clinical Centre Rosenheim   (Germany)

^h Lutonix Inc   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

angioplasty; drug coated balloon; drug eluting balloon; paclitaxel; peripheral vascular disease; restenosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; POLYSORBATE; SORBITOL;

ADVERSE OUTCOME; AGED; AMPUTATION; ANGIOGRAPHY; AREA UNDER THE CURVE; ARTICLE; BALLOON CATHETER; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE MALFUNCTION; DRUG BLOOD LEVEL; DRUG ELUTING STENT; FEMALE; FEMORAL ARTERY; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; LOADING DRUG DOSE; LOW DRUG DOSE; LUMEN LOSS; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICAL DEVICE COMPLICATION; MORTALITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; PHARMACOKINETICS; POPLITEAL ARTERY; PRIORITY JOURNAL; REVASCULARIZATION; SINGLE BLIND PROCEDURE; STENT THROMBOSIS; ARTERY OCCLUSION; ARTERY THROMBOSIS; CAUSE OF DEATH; DEVICE SAFETY; EVENT FREE SURVIVAL; FEMOROPOPLITEAL RESTENOSIS; FUNCTIONAL STATUS; INTENTION TO TREAT ANALYSIS; LUTONIX PACLITAXEL COATED BALLOON; MEAN RESIDENCE TIME; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY BALLOON; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ANGIOPLASTY; DCB; DRUG-COATED BALLOON; DRUG-COATED BALLOON(S); DRUG-ELUTING BALLOON; INTENTION TO TREAT; ITT; LATE LUMEN LOSS; LLL; PACLITAXEL; PERIPHERAL VASCULAR DISEASE; PHARMACOKINETICS; PK; RESTENOSIS; TARGET LESION REVASCULARIZATION(S); TLR;

AGED; AGED, 80 AND OVER; AMPUTATION; ANGIOPLASTY, BALLOON; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CONSTRICTION, PATHOLOGIC; DRUG CARRIERS; EQUIPMENT DESIGN; EUROPE; FEMALE; FEMORAL ARTERY; HUMANS; LIMB SALVAGE; MALE; MIDDLE AGED; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POLYSORBATES; POPLITEAL ARTERY; RECURRENCE; SORBITOL; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ACCESS DEVICES;

EID: 84892987217     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2013.05.022     Document Type: Article

References (27)

1. M.T. Abola, D.L. Bhatt, S. Duval for the REACH Investigators Fate of individuals with ischemic amputations in the REACH Registry: three-year cardiovascular and limb-related outcomes Atherosclerosis 221 2012 527 535
2. E.M. Mahoney, K. Wang, H.H. Keo for the REACH Registry Investigators Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States Circ Cardiovasc Qual Outcomes 3 2010 642 651
3. J.M. Peacock, H.H. Keo, and S. Duval et al. The incidence and health economic burden of ischemic amputation in Minnesota, 2005-2008 Prev Chronic Dis 8 2011 A141
4. A.T. Hirsch, Z.J. Haskal, and N.R. Hertzer et al. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease) - summary of recommendations J Vasc Interv Radiol 17 2006 1383 1397
5. L. Norgren, W.R. Hiatt, J.A. Dormandy for the TASC II Working Group Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) J Vasc Surg 45 Suppl S 2007 S5 S67
6. P. Dick, S. Sabeti, and W. Mlekusch et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience Radiology 248 2008 297 302
7. K.J. Rocha-Singh, M.R. Jaff, T.R. Crabtree for VIVA Physicians Inc Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease Catheter Cardiovasc Interv 69 2007 910 919 (Pubitemid 46867500)
8. H. Krankenberg, M. Schlüter, and H.J. Steinkamp et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the Femoral Artery Stenting Trial (FAST) Circulation 116 2007 285 292 (Pubitemid 47196564)
9. M. Bosiers, K. Deloose, and J. Callaert et al. Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions J Vasc Surg 54 2011 1042 1050
10. M. Schillinger, S. Sabeti, and C. Loewe et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery N Engl J Med 354 2006 1879 1888 (Pubitemid 43872689)
11. J.R. Laird, B. Katzen, D. Scheinert for the RESILIENT Investigators Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial Circ Cardiovasc Interv 3 2010 267 276
12. D.S. Steinfeld, A.P. Liu, and S.H. Hsu et al. Comparative assessment of transient exposure of paclitaxel or zotarolimus on in vitro vascular cell death, proliferation, migration, and pro-inflammatory biomarker expression J Cardiovasc Pharmacol 60 2012 179 186
13. B. Scheller, U. Speck, and B. Romeike et al. Contrast media as carriers for local drug delivery: successful inhibition of neointimal proliferation in the porcine coronary stent model Eur Heart J 24 2003 1462 1467 (Pubitemid 36961837)
14. B. Scheller, U. Speck, C. Abramjuk, U. Bernhardt, M. Bōhm, and G. Nickenig Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis Circulation 110 2004 810 814 (Pubitemid 39096008)
15. B. Scheller, C. Hehrlein, and W. Bocksch et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter N Engl J Med 355 2006 2113 2124 (Pubitemid 44749319)
16. M. Unverdorben, C. Vallbracht, and B. Cremers et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis Circulation 119 2009 2986 2994
17. G. Tepe, T. Zeller, and T. Albrecht et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg N Engl J Med 358 2008 689 699 (Pubitemid 351240748)
18. M. Werk, S. Langner, and B. Reinkensmeier et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial Circulation 118 2008 1358 1365
19. M.W. Krucoff, D.J. Kereiakes, J.L. Petersen for the COSTAR II Investigators Group A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study J Am Coll Cardiol 51 2008 1543 1552 (Pubitemid 351512313)
20. A.J. Lansky, R.A. Costa, G.S. Mintz for the DELIVER Clinical Trial Investigators Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial Circulation 109 2004 1948 1954 (Pubitemid 38544484)
21. G.W. Stone, S.G. Ellis, D.A. Cox for the TAXUS-IV Investigators A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231 (Pubitemid 38067635)
22. J. Aoki, A.T. Ong, and A. Abizaid et al. One-year clinical outcome of various doses and pharmacokinetic release formulations of paclitaxel eluted from an erodable polymer: insight in the Paclitaxel In-Stent Controlled Elution Study (PISCES) EuroIntervention 1 2005 165 172
23. B. Cremers, M. Biedermann, D. Mahnkopf, M. Böhm, and B. Scheller Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model Clin Res Card 98 2009 325 330
24. A. Pósa, N. Nyolczas, and R. Hemetsberger et al. Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries Catheter Cardiovasc Interv 76 2010 395 403
25. M. Unverdorben, F.X. Kleber, and H. Heuer et al. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter Clin Res Cardiol 99 2010 165 174
26. B. Cortese, A. Micheli, and A. Picchi et al. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial: the PICCOLETO study Heart 96 2010 1291 1296
27. L. Gianni, C.M. Kearns, and A. Giani et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans J Clin Oncol 13 1995 180 190